Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Molecular doorstop could be key to new tuberculosis drugs

20.03.2018

Tuberculosis, which infects roughly one quarter of the world's population and kills nearly two million people a year, is not only deadly but ancient: signs of the disease have been found in Egyptian mummies. Despite its age, Mycobacterium tuberculosis, the pathogen that causes the illness, continues to learn new tricks. It has a particular knack for evolving antibiotic resistance, leaving hundreds of thousands of people with few treatment options.

Now, research conducted by Rockefeller scientists under the direction of Seth Darst, the Jack Fishman Professor, and Elizabeth Campbell, a senior research associate in Darst's laboratory, offers hope for a new and potent weapon against tuberculosis.


RNA polymerase, an enzyme essential to life, uses a specialized clamp to latch onto DNA.

Credit: Laboratory of Molecular Biophysics at The Rockefeller University

Usage Restrictions: Image may be used only to illustrate the research described in the accompanying release.

Their work, which appears in eLife, focuses on an antibiotic that kills M. tuberculosis in the laboratory, but is not suitable for clinical use. By explaining how the drug operates, their research might allow others to design new antibiotics that could in fact be used to treat tuberculosis patients--and might even work on other bugs.

A flawed candidate

Campbell explains that the antibiotic in question, fidaxomicin, is uncommonly adept at killing M. tuberculosis cultivated in the lab. To be useful against tuberculosis in the real world, however, an antibiotic must be absorbed by the gut and eventually reach the lungs when taken orally--something that fidaxomicin cannot do.

Fidaxomicin targets an enzyme called RNA polymerase (RNAP), which transcribes DNA into RNA, a process fundamental to life. The enzyme possesses a hinged pincer, or clamp, that swings shut to secure DNA for transcription.

Scientists suspected that the drug works by somehow interfering with this clamp. But they didn't know precisely how the molecule went about its job--knowledge that would be essential to creating more useful versions of fidaxomicin.

By using a powerful imaging technique known as cryo-electron microscopy, however, Campbell and her colleagues were able to figure out exactly how the antibiotic throws a wrench into RNAP.

Open wide

Thanks to earlier research, the team already knew that the version of the enzyme found in M. tuberculosis only works properly when combined with a protein called RbpA--a transcription factor not found in all bacteria. RbpA winds itself into a narrow pocket located at the base of the RNAP clamp, making it fully functional. Using cryo-EM, post-doctoral fellow Hande Boyaci and graduate student James Chen were able to show for the first time that fidaxomicin binds to RbpA as well as other parts of the RNAP deep inside that pocket.

What's more, they were able to pinpoint what happens when the two molecules come together: fidaxomicin physically jams the enzyme's clamp open and won't allow it to close.

"It acts like a doorstop, and prevents the clamp from securing DNA for transcription," says Campbell.

Endless possibilities

Next, Campbell and her associates went a step further. Working with a non-pathogenic cousin of M. tuberculosis called M. smegmatis, the team used a mutant form of the bacteria that lacked the part of RbpA that interacts with fidaxomicin. When exposed to fidaxomicin, normal Mycobacteria could not grow. The mutants, however, were able to thrive despite the presence of the antibiotic and went about multiplying as usual, confirming what the researchers already suspected: that RbpA is an essential part of the mechanism that makes these microbes vulnerable to the drug.

Medicinal chemists might be able to use this insight into how fidaxomicin works to design versions of the antibiotic that are absorbed through the gut, or to identify other drugs that also bind in the RNAP pocket and interact with RpbA. Antibiotics that require RbpA to work would be very useful since they would kill only the select group of bacteria that contain RbpA. Antibiotics that kill indiscriminately can cause significant collateral damage, wiping out benevolent bacteria and breeding resistance among more dangerous ones.

At the same time, because all bacterial RNAP possesses the same pocket that fidaxomicin uses as its binding site, drug developers might also be able to use the team's structural data to develop antibiotics that kill bugs that do not rely upon RbpA at all.

"Our hope is that drug companies will use these studies as a platform for modifying and designing antimicrobials," says Campbell. "They could use the structures we analyzed to design antibiotics that would only inhibit Mycobacteria, but they could probably also design broad-spectrum antibiotics that would kill a wide range of other bacteria."

Media Contact

Katherine Fenz
kfenz@rockefeller.edu
212-327-7913

 @rockefelleruniv

http://www.rockefeller.edu 

Katherine Fenz | EurekAlert!

More articles from Life Sciences:

nachricht Zebrafish's near 360 degree UV-vision knocks stripes off Google Street View
22.06.2018 | University of Sussex

nachricht New cellular pathway helps explain how inflammation leads to artery disease
22.06.2018 | Cedars-Sinai Medical Center

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Temperature-controlled fiber-optic light source with liquid core

In a recent publication in the renowned journal Optica, scientists of Leibniz-Institute of Photonic Technology (Leibniz IPHT) in Jena showed that they can accurately control the optical properties of liquid-core fiber lasers and therefore their spectral band width by temperature and pressure tuning.

Already last year, the researchers provided experimental proof of a new dynamic of hybrid solitons– temporally and spectrally stationary light waves resulting...

Im Focus: Overdosing on Calcium

Nano crystals impact stem cell fate during bone formation

Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...

Im Focus: AchemAsia 2019 will take place in Shanghai

Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.

Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...

Im Focus: First real-time test of Li-Fi utilization for the industrial Internet of Things

The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.

Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.

Im Focus: Sharp images with flexible fibers

An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.

Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Munich conference on asteroid detection, tracking and defense

13.06.2018 | Event News

2nd International Baltic Earth Conference in Denmark: “The Baltic Sea region in Transition”

08.06.2018 | Event News

ISEKI_Food 2018: Conference with Holistic View of Food Production

05.06.2018 | Event News

 
Latest News

Graphene assembled film shows higher thermal conductivity than graphite film

22.06.2018 | Materials Sciences

Fast rising bedrock below West Antarctica reveals an extremely fluid Earth mantle

22.06.2018 | Earth Sciences

Zebrafish's near 360 degree UV-vision knocks stripes off Google Street View

22.06.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>